Advanced search for publications
Enter your keywords
Brolucizumab for wet age-related macular degeneration
Brolucizumab is a monoclonal antibody specific for vascular endothelial growth factor (VEGF). It is indicated for treatment of wet age-related macular degeneration (AMD), and is administered as an intravitreal injection every eight or 12 weeks. Download the full review below to read more.